Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
Rhea-AI Summary
Edgewise Therapeutics (NASDAQ: EWTX) has announced a webcast event scheduled for April 2, 2025, at 8:30 am ET to present top-line results from their Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with hypertrophic cardiomyopathy (HCM). The 28-day trial evaluated EDG-7500 in both obstructive and nonobstructive HCM patients.
The webcast will feature presentations from the management team alongside two CIRRUS-HCM investigators, described as world leaders in HCM patient care. The event will include an accompanying slide presentation, with registration available through the Edgewise events page.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EWTX gained 5.30%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
About EDG-7500
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2).
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X, Facebook and Instagram.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-time-302412513.html
SOURCE Edgewise Therapeutics
FAQ
When will Edgewise Therapeutics (EWTX) release the Phase 2 CIRRUS-HCM trial results?
What is the duration of the EWTX CIRRUS-HCM trial for EDG-7500?
Which patient types were included in the EWTX Phase 2 CIRRUS-HCM study?
Who will present the EWTX CIRRUS-HCM trial results?
